MacroGenics, Inc. (MGNX)
Stock Price:
$22.84 USD
0.43 (1.92%)
Updated November 25, 4:00 PM EST - Market closed
Key Info
| Market Cap |
1.28B |
| Revenue (ttm) |
77.38M |
| Net Income (ttm) |
-158.05M |
| Shares Out |
56.20M |
| EPS (ttm) |
-3.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$22.84 |
| Previous Close |
$22.41 |
| Change ($) |
0.43 |
| Change (%) |
1.92% |
| Day's Open |
22.47 |
| Day's Range |
22.30 - 23.36 |
| Day's Volume |
374,726 |
| 52-Week Range |
4.04 - 32.18 |
More Stats
| Market Cap |
1.28B |
| Enterprise Value |
1.03B |
| Earnings Date (est) |
Mar 2, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.20M |
| Float |
54.55M |
| EPS (basic) |
-3.13 |
| EPS (diluted) |
-3.12 |
| FCF / Share |
-2.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.14M |
| Short Ratio |
9.69 |
| Short % of Float |
7.59% |
| Beta |
2.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
16.59 |
| PB Ratio |
4.19 |
| Revenue |
77.38M |
| Operating Income |
-167.55M |
| Net Income |
-158.05M |
| Free Cash Flow |
-148.00M |
| Net Cash |
252.20M |
| Net Cash / Share |
4.49 |
| Gross Margin |
-169.44% |
| Operating Margin |
-216.51% |
| Profit Margin |
-204.20% |
| FCF Margin |
-191.26% |
| ROA |
-28.85% |
| ROE |
-57.81% |
| ROIC |
-105.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (11)
| Buy |
8 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
2 |
Price Target
$28.33*
(24.04% upside)
Low
8.00
Current: $22.84
High
38.00
Target: 28.33
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 64.19 | 60.12 | 158 | 91.88 | 101 | 47.80 | 58.04 | 63.83 | 57.21 |
| Revenue Growth | 6.76% | -61.89% | 71.68% | -8.9% | 111% | -17.64% | -9.07% | 11.57% | - |
| Gross Profit | 64.19 | 60.12 | 158 | 91.88 | 101 | 47.80 | 58.04 | 63.83 | 57.21 |
| Operating Income | -177 | -171 | -22.14 | -60.04 | -20.18 | -38.32 | 0.37 | 8.21 | 5.25 |
| Net Income | -152 | -171 | -19.63 | -58.53 | -20.14 | -38.31 | -0.26 | 8.36 | 6.72 |
| Shares Outstanding | 48.08 | 40.93 | 36.10 | 34.69 | 31.80 | 27.38 | 6.85 | 1.08 | 1.03 |
| Earnings Per Share | -3.16 | -4.19 | -0.54 | -1.69 | -0.63 | -1.40 | -0.04 | - | - |
| Operating Cash Flow | -134 | -153 | 14.41 | -43.68 | -13.66 | -32.76 | -14.17 | -6.58 | 6.76 |
| Capital Expenditures | -4.29 | -24.95 | -29.40 | -11.38 | -9.20 | -3.57 | -2.96 | -0.94 | -0.50 |
| Free Cash Flow | -139 | -178 | -15.00 | -55.06 | -22.86 | -36.33 | -17.13 | -7.52 | 6.26 |
| Cash & Equivalents | 216 | 233 | 305 | 277 | 339 | 158 | 117 | 48.15 | 55.80 |
| Total Debt | 30.57 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 185 | 233 | 305 | 277 | 339 | 158 | 117 | 48.15 | 55.80 |
| Assets | 313 | 332 | 374 | 311 | 359 | 174 | 126 | 53.75 | 62.68 |
| Liabilities | 81.87 | 89.25 | 74.65 | 42.51 | 45.93 | 52.60 | 46.87 | 61.98 | 80.16 |
| Book Value | 231 | 243 | 299 | 269 | 313 | 121 | 78.91 | -8.24 | 0.27 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
MacroGenics, Inc. |
| Country |
United States |
| Employees |
384 |
| CEO |
Scott E. Koenig |
Stock Information
| Ticker Symbol |
MGNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MGNX |
| IPO Date |
October 10, 2013 |
Description
MacroGenics, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.